"Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine (Sorbolene) Cream"

PHASE3CompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

October 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

Cavilon (TM) Durable Barrier Cream

Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.

DRUG

Sorbolene

Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation

RADIATION

Radiotherapy

Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol

Trial Locations (12)

1871

Liverpool Hospital, Liverpool

2031

Prince of Wales Hospital, Randwick

2145

Westmead Hospital, Wentworthville

2217

St George Hospital, Kogarah

2298

Calvary Mater Newcastle, Newcastle

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4029

Royal Brisbane Hospital, Herston

4101

Mater QRI, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

5000

Royal Adelaide Hospital, Adelaide

6000

Royal Perth Hospital, Perth

Unknown

Wollongong Hospital, Wollongong

All Listed Sponsors
collaborator

3M

INDUSTRY

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00193908 - "Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine (Sorbolene) Cream" | Biotech Hunter | Biotech Hunter